STOCKHOLM, May 13, 2025 /PRNewswire/ —
January 1 – March 31, 2025
The first quarter in figures
- Net sales were TSEK 8,856 (6,057), +46%.
- The loss after tax was TSEK 27,510 (10,861).
- The loss per share was SEK 0.09 (0.09).
- The cash flow from current operations was negative in the amount of TSEK 26,001 (13,182).
- The gross margin was 70.5% (69.9%).
- Electrode sales volume increased by 30% and was 17,870 (13,724) units. Repeat sales of electrodes to existing customers increased by 20%.
Important events during the quarter
- Overall sales increased by 46% (+45%, before currency effects). Sales in Germany within the skin cancer segment increased by 14% (14% in local currency). Sales in the US skin cancer market increased by 306% (295% in local currency) while the sales within the skin barrier segment decreased by 10%.
- SciBase announced that Mayo Clinic, the leading US hospital, will test Nevisense in a Pilot.
- SciBase announced the final outcome of directed issue and rights issue.
- Nevisense (EIS) included in updated German (S1) imaging guidelines and mentioend as a technology for detecting Melanoma and Non-Melanoma skin cancer.
- SciBase continues to expand in the US, on-boarding Several US Dermatology Practices that Specialize in Skin Cancer Detection.
Important events after the end of the period
- SciBase announced the launch of the next generation of Nevisense; Nevisense V.
|
Apr 1, 2024 – |
||||
|
Jan 1 – March 31 |
March 31, 2025 |
Jan 1 – Dec 31 |
||
|
THE GROUP |
2025 |
2024 |
Rolling-12 |
2023 |
|
Net sales, SEK ths |
8 856 |
6 057 |
32 503 |
29 705 |
|
Gross margin, % |
70,5 % |
69,9 % |
71,0 % |
71,0 % |
|
Equity/Asset ratio, % |
71,6 % |
58,2 % |
65,5 % |
59,4 % |
|
Net indebtness, multiple |
0,40 |
0,72 |
0,53 |
0,68 |
|
Cash equivalents, SEK ths |
34 295 |
20 272 |
34 295 |
11 245 |
|
Cashflow from operating activities, SEK ths |
-26 001 |
-13 182 |
-70 203 |
-57 383 |
|
Earnings per share (before and after dilution), SEK |
-0,09 |
-0,09 |
-0,35 |
-0,34 |
|
Shareholder’s equity per share, SEK |
0,14 |
0,25 |
0,16 |
0,21 |
|
Average number of shares, 000’* |
298 710 |
119 831 |
222 713 |
177 994 |
|
Number of shares at closing of period, 000’* |
338 296 |
119 831 |
338 296 |
219 538 |
|
Share price at end of period, SEK |
0,42 |
0,39 |
0,42 |
0,41 |
|
Number of sold electrodes, pieces |
17 870 |
13 724 |
66 356 |
62 210 |
|
Average number of employees |
35 |
26 |
28 |
28 |
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 13, 2025.
This interim report report has not been subject to review by the Company’s auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/interim-report,c4149173
The following files are available for download:
